Visible Genomics Wins 2025 AMD Genetic Testing Company of the Year Award

Visible Genomics, a provider of genetic testing solutions for severe ocular diseases, was named 'Life Sciences Review AMD Genetic Testing Company of the Year 2025.' This award recognizes the company’s innovative contributions to proactive care for advanced age-related macular degeneration (AMD).

Visible Genomics is aiming to transform the landscape of eye care by redefining how AMD risk factors are evaluated and addressed. According to Visible Genomics, recognizing that genetics may account for up to 70 percent of the chance of developing advanced AMD, the company’s proprietary AMD genetic tests aim to empower eye care professionals with a deeper understanding of a patient’s unique genetic risk, enabling earlier interventions and personalized treatment strategies.

“We are thrilled to be recognized for our commitment to advancing preventative eye care,” Scott Rediger, CEO of Visible Genomics, said in a company news release. “By leveraging the power of genetics, we can identify individuals at risk for AMD early on, allowing for timely interventions and potentially mitigating vision loss before it becomes irreversible.”

The company’s flagship products are the AMDiGuard lifetime test and AMDiGuard progression test. The lifetime test facilitates early awareness for individuals that are at high genetic risk but do not show signs or symptoms of AMD, while the progression test analyzes the risk of advanced AMD in patients who are already in the early or intermediate stages of the disease. Both tests aim to help prevent irreversible vision loss.

The AMDiGuard tests utilize a simple cheek swab to collect DNA, and samples are processed in a CLIA-certified laboratory, ensuring accurate and reliable results. Results are digitally delivered to eye care professionals in a HIPAA-compliant format for evaluation. The doctor/patient consultation is part of the design of a personalized health and wellness plan to delay potential onset or slow progression of advanced AMD.

Visible Genomics is partnering with medical education providers and academic institutions to integrate genomic insights into professional training and practice.